Cytotoxic T lymphocyte antigen-4 (CTLA-4)

Gizem Fidan Arslan; Ebru Karadağ Sarı

doi:10.5281/zenodo.18109341

Authors

Gizem Fidan Arslan Selçuk University, Institute of Health Sciences, Department of Histology and Embryology, Konya, Türkiye https://orcid.org/0000-0002-4316-5900
Ebru Karadağ Sarı Department of Histology and Embryology, Faculty of Veterinary Medicine, Kafkas University, Kars, Türkiye https://orcid.org/0000-0001-7581-6109

DOI:

https://doi.org/10.5281/zenodo.18109341

Keywords:

CTLA-4, T lymphocyte, autoimmune disease, Cytotoxic T lymphocyte, CD4, CD8

Abstract

Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a T lymphocyte surface molecule that plays a role in regulating the immune response. This molecule also plays an important role in regulating T cell activation and can limit the T cell response in accordance with inflammatory conditions. CTLA-4 Ig is a soluble chimeric protein and has a negative regulatory function in the body. When a foreign substance tries to enter the body, T cells become active and if this response shows excessive activation, it can damage normal and healthy cells and tissues, so it should be kept under control. It has been reported that genetic diversity in CTLA-4 may play a role in the development of autoimmune diseases. It is recommended that CTLA-4 be investigated in more detail to examine its effects by looking at the levels of CTLA-4 in the course of autoimmune diseases. It is thought that further investigation of CTLA-4 may contribute to immunotherapy and cancer treatments.

References

Wong, CK, Lit LC, Tam LS, Li EK, Lam CW: Aberrant production of soluble molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford), 44(8): 989-94,2005.

Yılmaz H: Psoriasis Vulgarisli Hastalarda Sitotoksik T Lenfosit Antijeni 4 Gen Polimorfizinin Araştırılması. Selçuk Üniversitesi, Yüksek Lisans tezi,2013.

Buchbinder E, Desai A: CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology,39(1):98–106, 2016.

Miller KDD, Fidler-Benaoudia M, Keegan THH, Hipp HSS, Jemal A, Siegel RLL: Cancer statistics for adolescents andyoung adults. CA Cancer Journal for Clinicians, 70, 443–459,2020.

Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ: Anative soluble form of CTLA-4. Celluler Immunolgy,201(2):144-53,2000.

Beyaz F: T lenfositlerinin Gelişimi, Fonksiyonları ve Histokimyasal Özellikleri. Erciyes Üniversitesi Veterinerlik Fakültesi Dergisi, 1(1) 61-66,2004.

Karagöz B: İleri Evrede Kanserli Hastaların Periferik kanında CD4+CD25+ Ve CD8+ Regulatuvar Hücreleri. Gülhane Askeri Tıp Akademisi Haydarpaşa Eğitim Hastanesi, Uzmanlık tezi,2006.

Guyton AC ve Hall JE. Tıbbi Fizyoloji. 11. Basım. Nobel Tıp Kitabevleri. 419-439,2007.

Junqueira CL, Carneiro J,Abrahamsohn PA, dos Santos MF, Zorn TM. Temel Histoloji, Nobel Kitapevi, İstanbul, 232-233,2009.

Girgin A, Liman N, Özfiliz N, Özcan Z,Erdost H, Ergün L, Zık B, Özen A, Ergün E, Kocamış H ve Özer A. Temel Histoloji, Dora yayıncılık, 3.Baskı, Bursa 290-293,2016.

Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex. Annual Review Immunolgy, (5): 503-540, 1987.

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter: Moleculer Biology of the cell. Annals of Botany (91):401-405 ,2003.

Abbas AK ve Lichtman AH. Temel İmmünoloji. İstanbul Medikal Yayıncılık. 1-160, 2007.

Larosa DF, Orange JS: Lymphocytes. Journal of Allergy Clinical Immunolgy, 121(2 Suppl):364-9,2008.

Zhu J and Paul W: Peripheral CD4 T cell differentiation regulated by networks of cytokines and transcription factors. Immunological Review, 238(1):247-62,2010.

Famili F, Staal F. JT: The development of T cells from stem cells in mice and humans. National Library of Medicine, Future-Science OA. 3(3): FSO186,2017.

Hardley G, Derry S, Moore RA: Imiquimod for actinic keratosis: Systematic review and meta-analysis. Journal of Investigative Dermatology, 126(6):1251-5,2006.

Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM: Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity, 24(6):677-88,2006.

Aktaş S: Hepatopankreatobilier Tümörlerde Düzenleyici T Lenfositler ve Prognostik Önemi. Dokuz Eylül Üniversitesi, Doktora tezi,2014.

Delves JP,Martin JS,Burton RD,Roitt MI.Temel İmmünoloji,Atlas Kitapçılık,11.Baskı,Ankara, 197-199,2008.

Brunet JF, Denizot F, Luciani MF,Roux-Dosseto M, Suzan M ,Mattei MG, Golstein P:A new member of the immunoglobulin superfamily CTLA 4 .Nature, 328 267-70,1987.

Mitsuiki N, Schwab C, Grimbacher B: What did we learn from CTLA-4 insufficiency on the human immune system? Immunological Reviews, 287:33–49.2019.

Linsley P, Nadler SG, Bajorath J, Peach R, Leung HT, Rogers J, Bradshaw J, Stebbins M, Leytze G, Brady W et al: Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. Journal of Biological Chemistry, 270(25):15417-24,1995.

Ling V, Wu PW, Finnerty HF, Sharpe AH, Gray GS, Collins M :Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics, 60(3):341-55,1999.

Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A., Gauchat JF, Bonnefoy JY, Delneste Y: A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. European Journal of Immunolgy, 29(11):3596-602,1999.

Sayegh, MH ve Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection.The New England Journal Medicine, 338(25):1813-21,1998.

Gough SC:The genetics of Graves‟ disease. Endocrinolgy Metabolism Clincs of North America, 29(2):255-66,2000.

Simmonds MJ, Gough SCL: Unravelling the genetic complexity of autoimmune thyroid disease. Clinical Experimental Immunolgy, 136(1): 1–10,2004.

Gough, SC,Walker LS ve Sansom DM:CTLA4 gene polymorphism and autoimmunity. Immunological Review, 204: 102-115,2005.

Nussbaum RL, Mclnnes RR, Willard HF. Thompson Tıbbi Genetik, 6. baskı, Güneş kitapevi, İstanbul, 90-92,2005.

Wang XB, Zheng CY, Giscombe R, Lefvert AK: Regulation of surface and intacellular expression of CTLA4 on human peripheral T cells. Scandinavian Journal of Immunolgy, 54(5):453-8,2001.

Chambers CA, Sullivan TJ, Allison JP:Lymphoproliferation in CTLA-4 deficient mice is mediated by costimulation- dependent activation of CD4+ T cells. Immunity, (7): 885-95,1997

Fraser JH, Rincón M, McCoy KD, Le Gros G: CTLA-4 ligation attenuates AP-1, NF-AT and NF-kappaB activitiy in activated T cells. European Journal of Immunolgy, 29(3): 838-44,1999.

Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B, Hogg N, Garside P, Rudd CE: Reversal of the T cell receptor signal by CTLA-4. Science,313(5795):1972-5,2006.

Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nature Reviews Immunolgy, 18:485-497,2018.

Ikemizu S, Gilbert RJ, Fennelly JA, Collins AV, Harlos K, Jones EY, Stuart DI, Davis SJ. Strucuture and dimerization of a soluable form of B7-1. Immunity, 12(1):51-60,2000.

Sansom DM: CD28, CTLA-4 and their ligands: Who does what and to whom? Immunolgy, 1(2):169-77,2000.

Kamradt T, Mitchison NA: Tolerance and autoimmunity.The New England Journal of Medicine, 344(9):655-64,2001.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, David L: Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 31(2), 214–234,2018.

Jordan B.H, Bluestone JA: Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunolgical Reviews, 229(1): 41-66,2009.

Schreiber TH: The use of Foxp3 as a bomarker and progostic factor for malignant human tumors. Cancer Epidemiol Biomarkers Prevention, 16(10):1931-4,2007.

Gallimore A, Godkin A: Regulatory T cells and tumour immunity-observations in mice and men. Immunology, 123(2):157–163,2008.

Şimşek M, Tekin, SB, Bilici M: Immunological Agents Used in Cancer Treatment. The Eurasian Journal Medicine. 51(1): 90–94, 2019.

Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 423:506‐511,2003.

Toussirot E, Saas P, Deschamps M, Pouthier F, Perrot L, Perruche S, Chabod J, Tiberghien P, Wendling D: Increased production of soluable CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthrits Research & Therapy, 11(4): 101,2009.

Ishimoto T, Shimada M, Araya CE, Huskey J, Garin EH, Johnson RJ: Minimal change disease: a CD80 podocytopathy? Seminars in Nephrology, 31(4):320-5,2011.

Kılıç L: Ctla-4 Gen Polimorfizinin Türk toplumundaki Graves hastalığında araştırılması. İstanbul Üniversitesi, Uzmanlık tezi,2008.

Özkorucu D: Deneysel Nefrotik Sendromda Gherelin CD80 ve CTLA4’ün Rolü. Eskişehir Osmangazi Üniversitesi, Uzmanlık tezi,2012.

Çelmeli F: Tip 1 Diyabetli Türk Çocuklarında CTLA 4 Gen Polimorfizmi. Akdeniz Üniversitesi, Uzmanlık tezi,2005.

Çetintepe S: Ankilozan Spondilit Hastalarında Serum sCTLA-4 ile hastalık aktivasyonu arasındaki ilişki. AdnaN Menderes Üniversitesi. Uzmanlık tezi,2014.

Yıldırım A: Vitiligo Tanılı Olgularda CTLA 4 ve MYG1 Gen Polimorfizlerinin İncelenmesi. Afyon Kocatepe Üniversitesi, Yüksek Lisans tezi,2015.

İslamova F: Hashimoto Tanılı Olgularda Sitotoksik T Lenfosit İlişkili Protein-4 (CTLA 4) ve Selenoprotein s(SEPS1) Gen Polimorfizmlerinin İncelenmesi. Namık Kemal Üniversitesi,Yüksek Lisans tezi,2017.

Saverino D, Simone R,Bagnasco M ve Pesce G: The soluble CTLA-4 receptor and its role in autoimmune disease an update. Autoımmunity Highlights, 1(2):73-81,2010.

Cytotoxic T lymphocyte antigen-4 (CTLA-4)

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

Information

Make a Submission

Indexing

PUBLISHER